NCT04785326View on ClinicalTrials.gov

Efficacy, Safety, and Immunogenicity of Subcutaneous DMB-3115 Versus Stelara® in Patients With Moderate to Severe Chronic Plaque Psoriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

598

Participants

Timeline

Start Date

April 28, 2021

Primary Completion Date

February 10, 2022

Study Completion Date

November 16, 2022

Conditions
Moderate to Severe Chronic Plaque Psoriasis
Interventions
DRUG

DMB-3115

45mg or 90mg dose subcutaneous administration

DRUG

Stelara

45mg or 90mg dose subcutaneous administration

Trial Locations (2)

73071

Central Sooner Research, Norman

84088

Jordan Valley Dermatology Center, West Jordan

Sponsors
All Listed Sponsors
collaborator

Meiji Seika Pharma Co., Ltd.

INDUSTRY

lead

Dong-A ST Co., Ltd.

INDUSTRY

NCT04785326 - Efficacy, Safety, and Immunogenicity of Subcutaneous DMB-3115 Versus Stelara® in Patients With Moderate to Severe Chronic Plaque Psoriasis | Biotech Hunter | Biotech Hunter